Inhibrx schedules Sept. 8 webcast to release Phase 2 INBRX-106 first-line HNSCC study endpoint results
I
INBX• Sept. 8 webcast planned for Phase 2 HexAgon HNSCC results
Inhibrx scheduled a Sept. 8 webcast to present primary endpoint results from the Phase 2 portion of its HexAgon HNSCC study.
- Results have not yet been presented.
- The trial compares INBRX-106 with pembrolizumab versus pembrolizumab alone in first-line PD-L1 positive metastatic or recurrent head and neck cancer.
- The update could reset expectations for INBRX-106’s clinical profile, influencing pipeline prioritization and partnering interest.
XLE
•
Inhibrx schedules Sept. 8 webcast to release Phase 2 INBRX-106 first-line HNSCC study endpoint results - INBX News | Rallies
